Hodgkin Lymphoma
Conference Coverage
Novel targeted cancer drugs cause fewer arrhythmias
Tyrosine kinase inhibitors and other targeted agents have 40% lower cardiac arrhythmia risk than anthracycline-based regimens.
News
CHMP recommends approval for generic carmustine
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion of Carmustine Obvius, a...
News
FDA places tazemetostat trials on partial hold
The hold has halted enrollment in US-based trials of tazemetostat, but study subjects who have not experienced disease progression may continue to...
News
Art education benefits blood cancer patients
New research suggests a bedside visual art intervention (BVAI) can reduce pain and anxiety in inpatients with hematologic malignancies, including...
News
FDA approves BV plus chemo for untreated cHL
The US Food and Drug Administration (FDA) has approved brentuximab vedotin (ADCETRIS) in combination with chemotherapy for adults with previously...
News
FDA approves new option in Hodgkin lymphoma treatment
The approval is based on results from the ECHELON-1 trial in previously untreated patients with stage III or IV classical Hodgkin lymphoma.
News
Lymphoma, breast cancer survivors have greater risk of CHF
ORLANDO—Results of a retrospective study showed that survivors of lymphoma or breast cancer had a significantly greater risk of congestive heart...
News
FDA approves label update for nivolumab
The US Food and Drug Administration (FDA) has updated the label for nivolumab (Opdivo®) to include new dosing and administration information....
Conference Coverage
Study confirms higher risk of infection with CB transplant
SALT LAKE CITY—Results of a large, retrospective analysis support the notion that patients who receive cord blood (CB) transplants have a higher...
Conference Coverage
Expanded UCB product can stand alone
SALT LAKE CITY—The expanded umbilical cord blood (UCB) product NiCord can be used as a stand-alone graft, according to research presented at the...
Conference Coverage
Combo is preferentially active in T-cell lymphomas
LA JOLLA, CA—A 2-drug combination has demonstrated preferential activity in T-cell lymphomas over B-cell lymphomas, according to researchers. In a...